Stealth begins Phase II IDDEA-HF study of elamipretide to treat congestive heart failure

Stealth BioTherapeutics has initiated IDDEA-HF, a Phase 2 study evaluating elamipretide in patients hospitalised due to congestive heart failure.

Source: Drug Development Technology - October 26, 2016 Category: Pharmaceuticals Source Type: news